New drug combo aims to wipe out lingering cancer after transplant
NCT ID NCT05091372
Summary
This study is testing whether a two-drug combination (belantamab mafodotin plus lenalidomide) given as maintenance therapy after a patient's own stem cell transplant can help eliminate any remaining, hard-to-detect cancer cells in people with newly diagnosed multiple myeloma. The main goal is to see if this treatment can convert patients from having detectable residual disease to having no detectable disease. Researchers will also monitor the safety of the drugs and how long patients remain cancer-free.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOMA, MULTIPLE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77051, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.